Phoenix Molecular Designs Ltd.
$500,000.00 CAD
≈ 6 Canadians' average pay for a year
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2018-2019
- Agreement period
- April 1, 2018 – July 31, 2019
- Reference
- nrc-cnrc:172-2018-2019-Q1-904717
Published purpose
Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common receptor targets for current breast cancer chemotherapies. TNBC represents 15-25% of all breast cancers, and RSK represents a novel target for TNBC. PMD-026 is a first-in-class RSK inhibitor, and the proposed Project will assess pre-clinical safety of this lead compound in relevant animal models and investigate potential drug-drug interactions, in anticipation of IND submission and human trials.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported August 3, 2026 from open.canada.ca Grants & Contributions